BCTX — Briacell Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study
Brief: Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License
Brief: Briacell Therapeutics Announces Pricing Of $30 Million Public Offering At $5.59 Per Unit
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:51 AM
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Briacell Phase 3 Trial Featured In Nature Medicine
Brief: BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data Readout
Brief: Briacell And Receptor.Ai To Collaborate On Ai Driven Small Molecule Cancer Therapeutics
Brief: BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Brief: BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer
Brief: Briacell Awarded $2 Million Nci Grant To Advance Bria-Pros+™ In Prostate Cancer
Brief: Briacell Therapeutics Announces 1-For-10 Share Consolidation
Brief: Briacell Therapeutics Granted New Zealand Patent For Whole-Cell Cancer Vaccines
Brief: Briacell Therapeutics’ Subsidiary, BriaPro, Files Patent Application For Immuno-Oncology Platform With Novel Multitargeting Agents